- Home
- JGH vs MGTX Comparison
JGH vs MGTX Comparison
Compare JGH & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JGH | MGTX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.3M | 665.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JGH | MGTX |
|---|---|---|
| Price | $12.58 | $7.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $23.83 |
| AVG Volume (30 Days) | 73.9K | ★ 499.2K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,417,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $619.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 96.83 |
| 52 Week Low | $10.36 | $4.55 |
| 52 Week High | $12.85 | $9.73 |
Technical Indicators
Market Signals| Indicator | JGH | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 46.24 |
| Support Level | $12.51 | $7.66 |
| Resistance Level | $12.61 | $8.40 |
| Average True Range (ATR) | 0.07 | 0.52 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 79.99 | 16.85 |
Price Performance
Historical ComparisonAbout JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.